Bavarian Nordic names Sanofi, AstraZeneca veteran as next CEO
The Danish vaccine maker is turning to a pharma industry veteran to succeed longtime CEO Paul Chaplin.
Bavarian Nordic, the Danish vaccine maker, has selected a new chief executive to replace longtime CEO Paul Chaplin. Chaplin's exit was announced earlier this year, and the company has now lined up a successor with senior leadership experience across several major pharmaceutical companies, including Sanofi, AstraZeneca and Pfizer.
The incoming CEO's background spans both large-cap drugmakers and the vaccine space, which could prove relevant as Bavarian Nordic continues to build on its portfolio of vaccines for infectious diseases. The move signals continuity for the company during its leadership transition.
Since the report draws on a single source, there are no differing accounts to compare. The source does not specify the new CEO's name, exact start date, or prior titles, only that the executive is a veteran of Sanofi, AstraZeneca and Pfizer.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.